Autologous bone marrow stromal cells genetically engineered to secrete an IGF-I receptor decoy prevent the growth of liver metastases

Molecular Therapy

Volumn 17, Issue 7, 2009, Pages 1241-1249

  Wang, Ni ^a   Fallavollita, Lucia ^a   Nguyen, Long ^a   Burnier, Julia ^a   Rafei, Moutih ^b   Galipeau, Jacques ^b   Yakar, Shoshana ^c   Brodt, Pnina ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN C RECEPTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER INHIBITION; CARCINOGENESIS; CELL BASED GENE THERAPY; CELL CULTURE; COLON CARCINOMA; CONTROLLED STUDY; GENETIC ANALYSIS; GENETIC ENGINEERING; HUMAN; HUMAN CELL; IN VIVO GENE TRANSFER; INOCULATION; LIVER METASTASIS; LUNG CARCINOMA; MICROMETASTASIS; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STROMA CELL;

MUS;

ANIMALS; BLOTTING, WESTERN; BONE MARROW CELLS; CELL LINE; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MICE; RADIOIMMUNOASSAY; RECEPTOR, IGF TYPE 1; RETROVIRIDAE; STROMAL CELLS; TISSUE THERAPY;

EID: 67649867463     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2009.82     Document Type: Article

References (50)

1. Wei, AC, Greig, PD, Grant, D, Taylor, B, Langer, B and Gallinger, S (2006). Survival after hepatic resection for colorectal metastases: A 10-year experience. Ann Surg Oncol 13: 668-676.
2. Girnita, A, All-Ericsson, C, Economou, MA, Aström, K, Axelson, M, Seregard, S et al. (2006). The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells. Clin Cancer Res 12: 1383-1391.
3. LeBedis, C, Chen, K, Fallavollita, L, Boutros, T and Brodt, P (2002). Peripheral lymph node stromal cells can promote growth and tumorigenicity of breast carcinoma cells through the release of IGF-I and EGF. Int J Cancer 100: 2-8.
4. Long, L, Rubin, R, Baserga, R and Brodt, P (1995). Loss of the metastatic phenotype in murine carcinoma cells expressing an antisense RNA to the insulin-like growth factor receptor. Cancer Res 55 1006-1009.
5. Long, L, Rubin, R and Brodt, P (1998). Enhanced invasion and liver colonization by lung carcinoma cells overexpressing the type 1 insulin-like growth factor receptor. Exp Cell Res 238: 116-121.
6. Reinmuth, N, Liu, W, Fan, F, Jung, YD, Ahmad, SA, Stoeltzing, O et al. (2002). Blockade of insulin-like growth factor I receptor function inhibits growth and angiogenesis of colon cancer. Clin Cancer Res 8: 3259-3269.
7. Donovan, EA and Kummar, S (2008). Role of insulin-like growth factor-1R system in colorectal carcinogenesis. Crit Rev Oncol Hematol 66 91-98.
8. Samani, AA, Yakar, S, LeRoith, D and Brodt, P (2007). The role of the IGF system in cancer growth and metastasis: Overview and recent insights. Endocr Rev 28: 20-47.
9. Oshima, T, Akaike, M, Yoshihara, K, Shiozawa, M, Yamamoto, N, Sato, T et al. (2008). Clinicopathological significance of the gene expression of matrix metalloproteinase-7, insulin-like growth factor-1, insulin-like growth factor-2 and insulin-like growth factor-1 receptor in patients with colorectal cancer: Insulin-like growth factor-1 receptor gene expression is a useful predictor of liver metastasis from colorectal cancer. Oncol Rep 20: 359-364.
10. Sachdev, D and Yee, D (2007). Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 6: 1-12.
11. Arora, A and Scholar, EM (2005). Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 315: 971-979.
12. Jain, RK, Duda, DG, Clark, JW and Loeffler, JS (2006). Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3: 24-40.
13. Weroha, SJ and Haluska, P (2008). IGF-1 receptor inhibitors in clinical trials--early lessons. J Mammary Gland Biol Neoplasia 13: 471-483.
14. Ullrich, A, Gray, A, Tam, AW, Yang-Feng, T, Tsubokawa, M, Collins, C et al. (1986). Insulin-like growth factor I receptor primary structure: Comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J 5: 2503-2512.
15. Garrett, TP, McKern, NM, Lou, M, Frenkel, MJ, Bentley, JD, Lovrecz, GO et al. (1998). Crystal structure of the first three domains of the type-1 insulin-like growth factor receptor. Nature 394: 395-399.
16. Jansson, M, Hallén, D, Koho, H, Andersson, G, Berghard, L, Heidrich, J et al. (1997). Characterization of ligand binding of a soluble human insulin-like growth factor I receptor variant suggests a ligand-induced conformational change. J Biol Chem 272: 8189-8197.
17. Denley, A, Cosgrove, LJ, Booker, GW, Wallace, JC and Forbes, BE (2005). Molecular interactions of the IGF system. Cytokine Growth Factor Rev 16: 421-439.
18. Yakar, S, Rosen, CJ, Beamer, WG, Ackert-Bicknell, CL, Wu, Y, Liu, JL et al. (2002). Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest 110: 771-781.
19. Bauer, TW, Fan, F, Liu, W, Camp, ER, Yang, A, Somcio, RJ et al. (2007). Targeting of insulin-like growth factor-I receptor with a monoclonal antibody inhibits growth of hepatic metastases from human colon carcinoma in mice. Ann Surg Oncol 14: 2838-2846.
20. Becker, CM, Farnebo, FA, Iordanescu, I, Behonick, DJ, Shih, MC, Dunning, P et al. (2002). Gene therapy of prostate cancer with the soluble vascular endothelial growth factor receptor Flk1. Cancer Biol Ther 1: 548-553.
21. Trieu, Y, Wen, XY, Skinnider, BF, Bray, MR, Li, Z, Claudio, JO et al. (2004). Soluble interleukin-13Ralpha2 decoy receptor inhibits Hodgkin's lymphoma growth in vitro and in vivo. Cancer Res 64: 3271-3275.
22. Rudge, JS, Thurston, G, Davis, S, Papadopoulos, N, Gale, N, Wiegand, SJ et al. (2005). VEGF trap as a novel antiangiogenic treatment currently in clinical trials for cancer and eye diseases, and VelociGene-based discovery of the next generation of angiogenesis targets. Cold Spring Harb Symp Quant Biol 70: 411-418.
23. Buckley, RH (2000). Gene therapy for human SCID: Dreams become reality. Nat Med 6: 623-624.
24. Baksh, D, Song, L and Tuan, RS (2004). Adult mesenchymal stem cells: characterization, differentiation, and application in cell and gene therapy. J Cell Mol Med 8: 301-316.
25. Horwitz, EM, Le Blanc, K, Dominici, M, Mueller, I, Slaper-Cortenbach, I, Marini, FC et al. (2005). Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy 7: 393-395.
26. Horwitz, EM (2006). MSC: A coming of age in regenerative medicine. Cytotherapy 8: 194-195.
27. Kumar, S, Chanda, D and Ponnazhagan, S (2008). Therapeutic potential of genetically modified mesenchymal stem cells. Gene Ther 15: 711-715.
28. Keating A, Guinn, BA, Laraya P and Wang XH (1996). Human marrow stromal cells electrotransfected with human FIX cDNA engraft in SCID mice and transcribe human Factor IX. Exp Hematol 24: 1056.
29. Eliopoulos N, Crosato, M and Galipeau, J (2000). High-level erythropoietin production from genetically engineered bone marrow stroma implanted in non-myeloablated, immunocompetent mice. Blood 96 802a.
30. Stagg, J, Wu, JH, Bouganim, N and Galipeau, J (2004). Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy. Cancer Res 64: 8795-8799.
31. Stagg, J and Galipeau, J (2007). Immune plasticity of bone marrow-derived mesenchymal stromal cells. Handb Exp Pharmacol: 45-66.
32. Samani, AA, Chevet, E, Fallavollita, L, Galipeau, J and Brodt, P (2004). Loss of tumorigenicity and metastatic potential in carcinoma cells expressing the extracellular domain of the type 1 insulin-like growth factor receptor. Cancer Res 64: 3380-3385.
33. Eliopoulos, N, Al-Khaldi, A, Crosato, M, Lachapelle, K and Galipeau, J (2003). A neovascularized organoid derived from retrovirally engineered bone marrow stroma leads to prolonged in vivo systemic delivery of erythropoietin in nonmyeloablated, immunocompetent mice. Gene Ther 10: 478-489.
34. Rudge, JS, Holash, J, Hylton, D, Russell, M, Jiang, S, Leidich, R et al. (2007). Inaugural Article: VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci USA 104: 18363-18370.
35. Wu, Y, Yakar, S, Zhao, L, Hennighausen, L and LeRoith, D (2002). Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res 62: 1030-1035.
36. Horwitz, EM, Gordon, PL, Koo, WK, Marx, JC, Neel, MD, McNall, RY et al. (2002). Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci USA 99: 8932-8937.
37. Tuason, MC, Rastikerdar, A, Kuhlmann, T, Goujet-Zalc, C, Zalc, B, Dib, S et al. (2008). Separate proteolipid protein/DM20 enhancers serve different lineages and stages of development. J Neurosci 28: 6895-6903.
38. Stripecke, R, Carmen Villacres, M, Skelton, D, Satake, N, Halene, S and Kohn, D (1999). Immune response to green fluorescent protein: implications for gene therapy. Gene Ther 6: 1305-1312.
39. Auguste, P, Fallavollita, L, Wang, N, Burnier, J, Bikfalvi, A and Brodt, P (2007). The host inflammatory response promotes liver metastasis by increasing tumor cell arrest and extravasation. Am J Pathol 170 1781-1792.
40. Khatib, AM, Auguste, P, Fallavollita, L, Wang, N, Samani, A, Kontogiannea, M et al. (2005). Characterization of the host proinflammatory response to tumor cells during the initial stages of liver metastasis. Am J Pathol 167: 749-759.
41. Khatib, AM, Fallavollita, L, Wancewicz, EV, Monia, BP and Brodt, P (2002). Inhibition of hepatic endothelial E-selectin expression by C-raf antisense oligonucleotides blocks colorectal carcinoma liver metastasis. Cancer Res 62: 5393-5398.
42. Kelley, KW, Weigent, DA and Kooijman, R (2007). Protein hormones and immunity. Brain Behav Immun 21: 384-392.
43. Prueitt, RL, Boersma, BJ, Howe, TM, Goodman, JE, Thomas, DD, Ying, L et al. (2007). Inflammation and IGF-I activate the Akt pathway in breast cancer. Int J Cancer 120: 796-805.
44. Reinmuth, N, Fan, F, Liu, W, Parikh, AA, Stoeltzing, O, Jung, YD et al. (2002). Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer. Lab Invest 82: 1377-1389.
45. Brodt, P (1986). Characterization of two highly metastatic variants of Lewis lung carcinoma with different organ specificities. Cancer Res 46: 2442-2448.
46. Yakar, S, Nunez, NP, Pennisi, P, Brodt, P, Sun, H, Fallavollita, L et al. (2006). Increased tumor growth in mice with diet-induced obesity: impact of ovarian hormones. Endocrinology 147: 5826-5834.
47. Kitadai, Y, Sasaki, T, Kuwai, T, Nakamura, T, Bucana, CD and Fidler, IJ (2006). Targeting the expression of platelet-derived growth factor receptor by reactive stroma inhibits growth and metastasis of human colon carcinoma. Am J Pathol 169: 2054-2065.
48. Campeau, PM, Rafei, M, François, M, Birman, E, Forner, KA and Galipeau, J (2009). Mesenchymal stromal cells engineered to express erythropoietin induce anti-erythropoietin antibodies and anemia in allorecipients. Mol Ther 17: 369-372.
49. Yakar, S, Bouxsein, ML, Canalis, E, Sun, H, Glatt, V, Gundberg, C et al. (2006). The ternary IGF complex influences postnatal bone acquisition and the skeletal response to intermittent parathyroid hormone. J Endocrinol 189: 289-299.
50. Pennisi, P, Gavrilova, O, Setser-Portas, J, Jou, W, Santopietro, S, Clemmons, D et al. (2006). Recombinant human insulin-like growth factor-I treatment inhibits gluconeogenesis in a transgenic mouse model of type 2 diabetes mellitus. Endocrinology 147: 2619-2630.